Welcome to our dedicated page for Kane Biotech news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech stock.
Kane Biotech Inc. (KNBIF, TSX-V: KNE) generates news primarily around its wound care biotechnology activities, especially the development and clinical use of its revyve ae Antimicrobial Wound Gel and Wound Gel Spray. Company updates frequently highlight how these products are designed to disrupt biofilms and address wound bacteria, which Kane Biotech identifies as key contributors to antibiotic resistance and complex wound outcomes.
News releases often cover regulatory milestones, such as FDA 510(k) clearances for revyve Antimicrobial Wound Gel and Spray, Health Canada approvals for the gel and spray, and the submission of a 510(k) application for revyve Antimicrobial Wound Cleanser. Investors and clinicians can also follow announcements about clinical and pre-clinical data, including case series in diabetic foot ulcers, burn wounds, chronic radiation-induced ulcers, venous leg ulcers, and other challenging wound types.
Kane Biotech regularly reports participation in wound care and burn conferences, where it presents data on healing trajectories, infection control, and biofilm management using revyve products. These events include meetings such as the Symposium on Advanced Wound Care, Diabetic Foot Conference, Southern Region Burn Conference, Innovations in Wound Healing, and other specialized gatherings.
In addition, the company issues news on financing and corporate developments, including private placement offerings, financial results, board and committee changes, and interactions with funding partners. For readers tracking KNBIF, this news page provides a centralized view of Kane Biotech’s scientific, regulatory, clinical, and corporate announcements related to its wound care biotechnology focus.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Kane Biotech reported robust financial performance in its fourth quarter and full year 2022 results, showing a 68% revenue increase to $691,654 for Q4, driven by growth in pet retail sales and licensing revenue. Total revenue for 2022 reached $2,668,352, a 66% increase from 2021. The company's gross profit surged 149% for the year to $1,413,229. Operating expenses decreased by 12%, leading to a 21% reduction in the annual loss to $3,824,000. Kane Biotech is focusing on advancing its clinical trials and expanding distribution agreements, including a notable partnership with ProgenaCare Global for its coactiv+™ Antimicrobial Wound Gel. The company maintains a strong cash position of $1.1 million as of December 31, 2022.
Kane Biotech has signed a distribution agreement with ProgenaCare Global LLC to commercialize its coactiv+™ Antimicrobial Wound Gel in the U.S. market. ProgenaCare will exclusively distribute the product once Kane receives 510(k) clearance from the FDA, triggering a $500,000 USD upfront payment. This gel targets the $200 million USD U.S. wound care hydrogel market, addressing the significant issues of chronic wounds, which are often resistant to treatment due to bacterial biofilms. CEO Marc Edwards emphasized the partnership's potential to disrupt the fragmented market with innovative wound care solutions. Together, Kane Biotech and ProgenaCare aim to improve health outcomes for patients while making treatment more accessible.